Susquehanna Fundamental Investments, LLC Gritstone Bio, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$1.96 - $2.9 $485,309 - $718,060	247,607 New	247,607 $636 Million
Q3 2023 Nov 14, 2023	SELL	$1.19 - $2.26 $10,682 - $20,288	-8,977 Reduced 29.39%	21,570 $37,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $3.92 $66,286 - $119,744	30,547 New	30,547 $105,000
Q1 2022 May 16, 2022	SELL	$4.03 - $12.19 $220,441 - $666,793	-54,700 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.76 - $13.71 $95,484 - $149,439	10,900 Added 24.89%	54,700 $703,000
Q3 2021 Nov 15, 2021	SELL	$6.41 - $13.54 $130,552 - $275,769	-20,367 Reduced 31.74%	43,800 $473,000
Q2 2021 Aug 11, 2021	SELL	$8.13 - $10.2 $22,438 - $28,151	-2,760 Reduced 4.12%	64,167 $586,000
Q1 2021 May 17, 2021	BUY	$4.07 - $27.11 $1,872 - $12,470	460 Added 0.69%	66,927 $631,000
Q4 2020 Feb 16, 2021	SELL	$2.57 - $4.22 $19,503 - $32,025	-7,589 Reduced 10.25%	66,467 $262,000
Q3 2020 Nov 16, 2020	BUY	$2.63 - $8.09 $143,842 - $442,466	54,693 Added 282.46%	74,056 $196,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $8.17 $110,175 - $158,195	19,363 New	19,363 $129,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.